医療関係者様へ
2022年発表論文
2022.02.26
2022年に当教室で発表した和文論文です。
| 題名（論文名） | 著者 | 掲載雑誌 |
|---|---|---|
| 【尿路性器感染症 治療・管理・再発防止のトピックス】(chapter 2)尿路性器感染症 複雑性膀胱炎． | 重原一慶 | Uro-Lo: 泌尿器Care & Cure 2022; 26(5): 642-646. |
| 進行腎癌患者におけるTKIによる高血圧に対するアジルサルタンとアムロジピンの降圧効果の比較検討． | 門本卓, 岩本大旭, 八重樫洋, 飯島将司, 川口昌平, 野原隆弘, 重原一慶, 泉浩二, 角野佳史, 溝上敦． | 日本腎泌尿器疾患予防医学研究会誌2022; 30(1): 58-59. |
| 【泌尿器科の疾患・治療・ケア】尿路感染症 急性前立腺炎・慢性前立腺炎/慢性骨盤痛症候群． | 重原一慶 | Uro-Lo: 泌尿器Care & Cure別冊泌尿器科の疾患・治療・ケア 2022; 113-119. |
| 【泌尿器科の疾患・治療・ケア】尿路感染症 精巣上体炎・精巣炎． | 重原一慶 | Uro-Lo: 泌尿器Care & Cure別冊泌尿器科の疾患・治療・ケア 2022; 120-126. |
| 【基礎から学ぶ 最新、泌尿器疾患の画像診断】骨シンチグラフィによる前立腺癌の骨転移診断 | 溝上敦、中嶋憲一 |
泌尿器外科2022; 35(5): 409-415. |
| 特集LOH症候群．LOH症候群の疫学． | 重原一慶，溝上敦． | 泌尿器科2022; 16: 6-10. |
| 男性の性腺機能低下症ガイドライン2022.前立腺癌に対する内分泌治療は代謝疾患のリスクを高めるか？ | 重原一慶． | 日内分泌学会誌 2022; 98(suppl): 100-104. |
| 【腎臓症候群(第3版)-その他の腎臓疾患を含めて-】腫瘍性腎疾患 腎腺腫(乳頭状腺腫,後腎性腺腫)． | 泉浩二 | 日本臨床2022; 9: 356-360. |
| 【おさえておくべき、Clinical trial!-進行性尿路上皮癌編-】進行性尿路上皮癌に対する免疫チェックポイント阻害薬の展望 IMvigor130試験から． | 泉浩二 | 泌尿器外科2022; 35(7): 596-601. |
2022年に当教室の医局員がfirst authorで発表した英文論文です。
| 題名（論文名） | 著者 | 掲載雑誌 |
|---|---|---|
| Variations in photodynamic diagnosis for bladder cancer due to the quality of endoscopic equipment. | Nohara T, Kamijima T, Fukuda R, Kano H, Shimada T, Nakano T, Kato Y, Kadomoto S, Iwamoto H, Yaegashi H, Iijima M, Kawaguchi S, Shigehara K, Izumi K, Kadono Y, Mizokami A. | Photodiagnosis Photodyn Ther. 2022; 37:102628. |
| Treatment Outcomes in Neuroendocrine Prostate Cancer. |
Iwamoto H, Nakagawa R, Makino T, Kadomoto S, Yaegashi H, Nohara T, Shigehara K, Izumi K, Kadono Y, Mizokami A. |
Anticancer Res. 2022; 42(4):2167-2176. |
| Ra-223 and Ethinylestradiol Combination Therapy in Castration-resistant Prostate Cancer. |
Shimada T, Izumi K, Kano H, Kadomoto S, Makino T, Naito R, Iwamoto H, Yaegashi H, Kadono Y, Mizokami A. |
Anticancer Res. 2022; 42(2): 1065-1071. |
| Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors. |
Nakagawa R, Iwamoto H, Makino T, Kadomoto S, Yaegashi H, Iijima M, Kawaguchi S, Nohara T, Shigehara K, Izumi K, Kadono Y, Mizokami A. |
Front Oncol. 2022; 11:770067. |
| Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer. |
Iwamoto H, Izumi K, Makino T, Mizokami A. |
Cancers (Basel). 2022 ;14(7):1803. |
| Survival Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Retrospective Single-institutional Experience. |
Yaegashi H, Nohara T, Shigehara K, Izumi K, Kadono Y, Makino T, Yamashita K, Ohtsubo K, Ikeda H, Mizokami A |
Cancer Diagn Progn. 2022; 2(3):352-359. |
| Investigating the mechanism underlying urinary continence using dynamic MRI after Retzius-sparing robot-assisted radical prostatectomy. |
Kadono Y, Nohara T, Kawaguchi S, Kadomoto S, Iwamoto H, Iijima M, Shigehara K, Izumi K, Yoshida K, Gabata T, Mizokami A. |
Sci Rep. 2022; 12(1):3975. |
| Influence of the Coronavirus Disease 2019 Vaccine on Drug Therapy for Urological Cancer. |
Kawaguchi S, Izumi K, Kadomoto S, Iwamoto H, Yaegashi H, Iijima M, Nohara T, Shigehara K, Kadono Y, Mizokami A. |
Anticancer Res. 2022; 42(4):2105-2111. |
| Impact of Pelvic Anatomical Changes Caused by Radical Prostatectomy. |
Kadono Y, Nohara T, Kawaguchi S, Iwamoto H, Yaegashi H, Shigehara K, Izumi K, Mizokami A. |
Cancers (Basel). 2022;14(13):3050. |
| Test clamp procedure in robot-assisted partial nephrectomy: is it a safe procedure? |
Nohara T, Kadomoto S, Iwamoto H, Yaegashi H, Iijima M, Kawaguchi S, Shima T, Shigehara K, Izumi K, Kadono Y, Seto C, Mizokami A. |
J Robot Surg. 2022;16(3):633-639. |
| Ischemic proctitis after low-dose-rate brachytherapy using hydrogel spacer for prostate cancer. |
Toriumi R, Yaegashi H, Sakurai T, Takamatsu S, Shigehara K, Izumi K, Kadono Y, Mizokami A. |
IJU Case Rep. 2022; 5(4):237-240. |
| Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial. | Izumi K, Shima T, Mita K, Kato Y, Kamiyama M, Inoue S, Tanaka N, Hoshi S, Okamura T, Yoshio Y, Enokida H, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Kadono Y, Mizokami A. | Eur Urol Open Sci. 2022; 41:16-23. |
| Epidemiology and Prevention of Renal Cell Carcinoma. |
Makino T, Kadomoto S, Izumi K, Mizokami A. |
Cancers (Basel). 2022;14(16):4059. |
| Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice. | Mizokami A, Nishimoto K, Matsuyama H, Ichikawa T, Takahashi S, Shiina H, Hashine K, Sugiyama Y, Kamiyama M, Enokida H, Nakajima K. | Anticancer Res. 2022; 42(3):1465-1475. |
| Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTAT-BSI Sub-analysis. | Kamijima T, Yaegashi H, Mizokami A, Nakajima K, Matsuyama H, Ichikawa T, Nishimoto K, Takahashi S, Shiina H, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A, Enokida H. | Anticancer Res. 2022; 42(6):3099-3108. |
| Usefulness of serum CCL2 as prognostic biomarker in prostate cancer: a long-term follow-up study. | Iwamoto H, Izumi K, Nakagawa R, Toriumi R, Aoyama S, Shimada T, Kano H, Makino T, Kadomoto S, Yaegashi H, Kawaguchi S, Nohara T, Shigehara K, Kadono Y, Mizokami A. | Jpn J Clin Oncol. 2022 Jun 20:hyac102. |
| The COVID-19 pandemic reduced the risk of febrile neutropenia during inpatient chemotherapy for urological cancer. | Toriumi R, Yaegashi H, Kadomoto S, Iwamoto H, Iijima M, Kawaguchi S, Nohara T, Shigehara K, Izumi K, Kadono Y, Mizokami A. | Cancer Sci. 2023; 114(1):201-210. (2022 Jul15:10.1111/cas.15490.) |
| The correlation between erectile function and adiponectin levels in men with late-onset hypogonadism. | Shigehara K, Kato Y, Konaka H, Kawaguchi S, Nohara T, Izumi K, Kadono Y, Namiki M, Mizokami A. | Aging male 2022; 25(1):249-254. |
| Comparison of Clinical Outcomes between Robot-Assisted Partial Nephrectomy and Cryoablation in Elderly Patients with Renal Cancer. | Kawaguchi S, Izumi K, Naito R, Kadomoto S, Iwamoto H, Yaegashi H, Nohara T, Shigehara K, Yoshida K, Kadono Y, Mizokami A. | Cancers (Basel). 2022;14(23):5843. |
| Relationship between testosterone and sarcopenia in older adult men; a narrative review. | Shigehara K, Kato Y, Izumi K, Mizokami A. | J Clin Med 2022; 11(20): 6202. |
| Carbon dioxide gas embolism during robot-assisted laparoscopic partial nephrectomy. | Nakagawa R, Nohara T, Kadomoto S, Iwamoto H, Yaegashi H, Iijima M, Kawaguchi S, Shigehara K, Izumi K, Kadono Y, Mizokami A. |
IJU Case Rep. 2022; 5(5):334-337. |
| Squamous or Glandular Differentiation Predicts Poor Prognosis in pT1 Urothelial Carcinoma. | Nakagawa R, Iwamoto H, Makino T, Kadomoto S, Yaegashi H, Shigehara K, Izumi K, Kadono Y, Mizokami A. | In Vivo. 2022; 36(5):2365-2370. |
| Development of a Prognostic Model of Overall Survival for Metastatic Hormone-Naïve Prostate Cancer in Japanese Men. | Nakagawa R, Iwamoto H, Makino T, Naito R, Kadomoto S, Akatani N, Yaegashi H, Kawaguchi S, Nohara T, Shigehara K, Izumi K, Kadono Y, Takamatsu A, Yoshida K, Mizokami A. | Cancers (Basel). 2022; 14(19):4822. |
| Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report. | Yoshida T, Yaegashi H, Toriumi R, Kadomoto S, Iwamoto H, Izumi K, Kadono Y, Ikeda H, Mizokami A. | Front Oncol. 2022; 12:912490. |
| Serum CCL2 Is a Prognostic Biomarker for Non-Metastatic Castration-Sensitive Prostate Cancer. | Iwamoto H, Izumi K, Nakagawa R, Toriumi R, Aoyama S, Kamijima T, Shimada T, Kano H, Makino T, Naito R, Kadomoto S, Yaegashi H, Kawaguchi S, Nohara T, Shigehara K, Kadono Y, Mizokami A. | Biomedicines. 2022; 10(10):2369. |
| Relationship between Testosterone and Sarcopenia in Older-Adult Men: A Narrative Review | Kazuyoshi Shigehara 1, Yuki Kato 1, Kouji Izumi 1, Atsushi Mizokami 1 | J Clin Med. 2022 Oct 20;11(20):6202. doi: 10.3390/jcm11206202. |
| Suppression of androgen receptor signaling induces prostate cancer migration via activation of the CCL20-CCR6 axis | Hiroshi Kano 1, Kouji Izumi 1, Kaoru Hiratsuka 1, Ren Toriumi 1, Ryunosuke Nakagawa 1, Shuhei Aoyama 1, Taiki Kamijima 1, Takafumi Shimada 1, Renato Naito 1, Suguru Kadomoto 1, Hiroaki Iwamoto 1, Hiroshi Yaegashi 1, Shohei Kawaguchi 1, Takahiro Nohara 1, Kazuyoshi Shigehara 1, Yoshifumi Kadono 1, Yohei Saito 2, Kyoko Nakagawa-Goto 2, Kazuaki Yoshioka 3, Hiroki Nakata 1 4, Wen-Jye Lin 5, Atsushi Mizokami 1 | Cancer Sci. 2022 Dec 7. doi: 10.1111/cas.15683. Online ahead of print. |
| Does Bladder Cancer with Inchworm Sign Indicate Better Prognosis after TURBT? | Ryunosuke Nakagawa 1, Kouji Izumi 1, Renato Naito 1, Suguru Kadomoto 1, Hiroaki Iwamoto 1, Hiroshi Yaegashi 1, Shohei Kawaguchi 1, Takahiro Nohara 1, Kazuyoshi Shigehara 1, Kotaro Yoshida 2, Yoshifumi Kadono 1, Atsushi Mizokami 1 | Cancers (Basel). 2022 Nov 23;14(23):5767. doi: 10.3390/cancers14235767. |